IMUX Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -- compared to Immunic, Inc.'s net margin of -10571.43%. Immunic, Inc.'s return on equity of -521.65% beat AIM ImmunoTech's return on equity of -256.33%.

Immunic, Inc. has a consensus price target of $5.38, signalling upside risk potential of 701.76%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Immunic, Inc., analysts believe AIM ImmunoTech is more attractive than Immunic, Inc..

Immunic, Inc. has a beta of 1.479, which suggesting that the stock is 47.918% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Immunic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunic, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Immunic, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Immunic, Inc.'s net income of -$25.6M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Immunic, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunic, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Immunic, Inc.'s net margin of --. Immunic, Inc.'s return on equity of -521.65% beat CEL-SCI Corp.'s return on equity of -266.61%.

Immunic, Inc. has a consensus price target of $5.38, signalling upside risk potential of 701.76%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 538.14%. Given that Immunic, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Immunic, Inc. is more attractive than CEL-SCI Corp..

Immunic, Inc. has a beta of 1.479, which suggesting that the stock is 47.918% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Immunic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunic, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Immunic, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Immunic, Inc.'s net income of -$25.6M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Immunic, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunic, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Immunic, Inc.'s net margin of -953.4%. Immunic, Inc.'s return on equity of -521.65% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Immunic, Inc. has a consensus price target of $5.38, signalling upside risk potential of 701.76%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1200.34%. Given that IGC Pharma, Inc. has higher upside potential than Immunic, Inc., analysts believe IGC Pharma, Inc. is more attractive than Immunic, Inc..

Immunic, Inc. has a beta of 1.479, which suggesting that the stock is 47.918% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Immunic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunic, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Immunic, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Immunic, Inc.'s net income of -$25.6M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Immunic, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunic, Inc. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Immunic, Inc.'s net margin of -255.85%. Immunic, Inc.'s return on equity of -521.65% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Immunic, Inc. has a consensus price target of $5.38, signalling upside risk potential of 701.76%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -53.04%. Given that Immunic, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Immunic, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Immunic, Inc. has a beta of 1.479, which suggesting that the stock is 47.918% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Immunic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Immunic, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immunic, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Immunic, Inc.'s net income of -$25.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Immunic, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunic, Inc. is -- versus 3.52x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.